Morphotek has signed a research collaboration agreement with Synageva to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.
Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP) technology and its expertise to produce and develop a therapeutic monoclonal antibody.
Philip Sass, Executive Vice President and Chief Operating Officer of Morphotek, said: “We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I.”